We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: JPMorgan, PayPal, Thermo Fisher Scientific, PepsiCo, McDonald's and Canadian National Railway
Read MoreHide Full Article
For Immediate Release
Chicago, IL – June 8, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: JPMorgan Chase & Co. (JPM - Free Report) , PayPal Holdings, Inc. (PYPL - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) , PepsiCo, Inc. (PEP - Free Report) , McDonald's Corporation (MCD - Free Report) and Canadian National Railway Company (CNI - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for JPMorgan, PayPal and Thermo Fisher
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase, PayPal Holdings, and Thermo Fisher Scientific. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of JPMorgan have outperformed the Zacks Major Regional Banks industry in the last one-year period (+51.4% vs. +47.2%). The Zacks analyst believes that branch openings in new regions, inorganic expansion strategies and strong mortgage banking business are expected to keep aiding financials in the upcoming quarters.
While the Fed's accommodative policy and near-zero rates are likely to hamper interest income and margins, a robust economic recovery will likely lead to rise in demand for loans. Furthermore, JPMorgan's impressive capital deployments reflect earnings strength and a solid balance sheet.
PayPal shares have gained +21.2% over the last six months against the Zacks Internet Software industry's loss of -11.7%. The Zacks analyst believes that PayPal is benefiting from robust growth in total payments volume owing to increasing net new active accounts.
Further, Venmo's improving monetization efforts and rising adoption rate across various platforms are aiding the total active accounts growth. Additionally, solid momentum of core peer to peer and PayPal Checkout experiences is a tailwind. Also, accelerating transaction revenues are likely to continue driving revenues.
Shares of Thermo Fisher have gained +2% in the past three months against the Zacks Medical Instruments industry's gain of +2.5%. The Zacks analyst believes that with several takeovers including Advanced Bioprocessing buyout from BD and Patheon, Thermo Fisher is expanding inorganic growth profile.
In terms of end market, pharma and biotech registered growth on robust performance in bioproduction and pharma services. However, the pandemic has massively disrupted the global supply chain. Foreign currency fluctuations and a competitive landscape are other major downsides.
Other noteworthy reports we are featuring today include PepsiCo, McDonald's and Canadian National Railway.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: JPMorgan, PayPal, Thermo Fisher Scientific, PepsiCo, McDonald's and Canadian National Railway
For Immediate Release
Chicago, IL – June 8, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: JPMorgan Chase & Co. (JPM - Free Report) , PayPal Holdings, Inc. (PYPL - Free Report) , Thermo Fisher Scientific Inc. (TMO - Free Report) , PepsiCo, Inc. (PEP - Free Report) , McDonald's Corporation (MCD - Free Report) and Canadian National Railway Company (CNI - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Analyst Reports for JPMorgan, PayPal and Thermo Fisher
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase, PayPal Holdings, and Thermo Fisher Scientific. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of JPMorgan have outperformed the Zacks Major Regional Banks industry in the last one-year period (+51.4% vs. +47.2%). The Zacks analyst believes that branch openings in new regions, inorganic expansion strategies and strong mortgage banking business are expected to keep aiding financials in the upcoming quarters.
While the Fed's accommodative policy and near-zero rates are likely to hamper interest income and margins, a robust economic recovery will likely lead to rise in demand for loans. Furthermore, JPMorgan's impressive capital deployments reflect earnings strength and a solid balance sheet.
(You can read the full research report on JPMorgan here >>>)
PayPal shares have gained +21.2% over the last six months against the Zacks Internet Software industry's loss of -11.7%. The Zacks analyst believes that PayPal is benefiting from robust growth in total payments volume owing to increasing net new active accounts.
Further, Venmo's improving monetization efforts and rising adoption rate across various platforms are aiding the total active accounts growth. Additionally, solid momentum of core peer to peer and PayPal Checkout experiences is a tailwind. Also, accelerating transaction revenues are likely to continue driving revenues.
(You can read the full research report on PayPal here >>>)
Shares of Thermo Fisher have gained +2% in the past three months against the Zacks Medical Instruments industry's gain of +2.5%. The Zacks analyst believes that with several takeovers including Advanced Bioprocessing buyout from BD and Patheon, Thermo Fisher is expanding inorganic growth profile.
In terms of end market, pharma and biotech registered growth on robust performance in bioproduction and pharma services. However, the pandemic has massively disrupted the global supply chain. Foreign currency fluctuations and a competitive landscape are other major downsides.
(You can read the full research report on Thermo Fisher here >>>)
Other noteworthy reports we are featuring today include PepsiCo, McDonald's and Canadian National Railway.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.